Terp Startup Synapto Looks to Change the Game for Diagnosing Alzheimer’s



Synapto co-founders Anoop Patel and David Boegner



Not in Terp Startup:



DC: How did you first come up with your idea?

Synapto: As members of the Biomedical Engineering Society, we were invited to participate in a medical device competition (DEBUT) sponsored by NIH. We had interest in machine learning and EEG and brainstormed ways to use data collected by EEG to let machine learning find patterns between healthy patients and those affected by Alzheimer’s Disease.

DC: What are some major milestones you’ve achieved so far?

Synapto: We have collaborated with institutions around the globe to retrieve EEG data from healthy and Alzheimer’s patients. Using this data along with software we created, we have been able to correctly classify around 80% of the patient dataset.

DC: What drives you to keep going?

Synapto: All of us in Synapto have a goal of making healthcare more accessible, and we believe what we are creating can contribute to this vision. Considering Alzheimer’s Disease is the most common form of dementia, we realize the huge potential impact we can have on accelerating the discovery of a cure.


Synapto: We love to hear about the work other student entrepreneurs are pursuing, and directly engaging with them allows us to learn about a wide range of ideas and technologies in a short timespan. It is amazing to be surrounded by people who are extremely passionate about what they are doing, as it inspires us to work even harder.


Synapto: During Terp Startup, we hope to grow both our data science and general business knowledge. With regards to Synapto specifically, we want to create a finalized data analysis pipeline and improve our machine learning algorithm to create a more accurate detection model. Furthermore, we wish to finalize preparations for our next major phase: conducting a clinical pilot study to collect proprietary data and perform our own data analytics.


Tagged , , , , ,

Leave a Reply

%d bloggers like this: